Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
Conditions: Adult Solid Neoplasm; Malignant Reproductive System Neoplasm; Malignant Urinary System Neoplasm; Metastatic Malignant Neoplasm; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Progressive Neoplastic Disease; Recurrent Bladder Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage III Bladder Urothelial Carcinoma; Stage III Urethral Cancer; Stage IV Bladder Urothelial Carcinoma; Stage IV Urethral Cancer; Urethral Urothelial CarcinomaInterventions: Drug: Cabozantinib S-malate; Biological: Nivolumab; Biological: Ipilimumab; Other: Laboratory Biomarker AnalysisSponsor: National Cancer Institute (NCI)Not yet recruiting - verified December 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Research | Ureter and Renal Pelvis Cancer | Urethral Cancer | Yervoy